Journal
FREE RADICAL RESEARCH
Volume 52, Issue 9, Pages 952-960Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10715762.2018.1500021
Keywords
Adriamycin; leonurine; oxidative stress; podocyte injury
Categories
Funding
- National Natural Science Foundation of China [81870469, 81670628, 81300573, 81530023, 81302768]
- Natural Science Foundation of Jiangsu Province [BK20131030]
- Natural Science Foundation of Shanghai [17ZR1418300]
- China Scholarship Council (CSC) [201608320124]
- Chinese Society of Nephrology [17010060675]
- Clinic Research Center of Jiangsu Province [BL2014080]
- Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institution
Ask authors/readers for more resources
Leonurine, a major bioactive component from Herba Leonuri, shows therapeutic potential in several diseases, including diabetes, cardiovascular disease, bovine mastitis and depression. In kidney, it was reported that leonurine was performing a protective effect in both acute kidney injury and renal fibrosis mice models. The aim of this study is to investigate the effect of leonurine in podocyte injury. In the mice model of adriamycin (ADR) -induced nephropathy, the application of leonurine significantly prevented early kidney damage, macrophage infiltration and proteinuria. Meanwhile, leonurine suppressed ADR-induced podocyte injury and reactive oxygen species (ROS) production. Consistent to in vivo results, leonurine prevented ADR-induced podocyte injury and ROS production in cultured human podocytes. All these results suggested that leonurine might suppress ADR-induced podocyte injury via inhibiting oxidative stress. Leonurine might be a novel therapeutic drug for prevention of glomerular diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available